Meike Wenzel

Patient Centricity: 4 key lessons you can learn from orphan disease companies

Without insights from Commercial functions at an earlier stage of drug development, R&D teams can miss crucial information which can cost pharma companies billions. Here, Executive Insight’s Meike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice.

We conducted a global study to understand to what extent beyond-the-pill strategies are and will be integrated into the pharmaceutical business model.

The race for therapeutic area leadership is one you need to win!

A short window of opportunity exists for pharmaceutical companies to establish indispensable beyond the pill services, which may even help them 'own' particular disease areas.

Biopharma companies are discovering that compelling and aligned services underpinned by a core strategy are providing them with distinctive competitive advantages.

We examine how the provision of services can give pharmaceutical companies an invaluable point of differentiation throughout the product life cycle.

In the first of a series of four articles, Executive Insight’s Meike Wenzel and Wendy van der Lubbe examine the increasing requirement for pharmaceutical companies to provide services ‘beyond the pill’ in order to improve health outcomes and be commercially successful.

A brief overview of access challenges and the regulatory process in Germany

Understanding and leveraging networks in the healthcare market (in German).

Die Entscheider im Pharmanetzwerk anhand ihrer Rollen erkennen.

A growing number of interrelated stakeholders (SHs) are gaining decisionmaking power in the health-care market. Pharmaceutical companies are still focusing most of their resources on a single SH group, prescribers. The lack of a systematic understanding of the infl uence of relationships between all SH groups has resulted in sales and marketing activities, which fail to address the issues pharmaceutical companies are faced with, such as low levels of public trust and decline in physician… Mehr anzeigen

A growing number of interrelated stakeholders (SHs) are gaining decisionmaking power in the health-care market. Pharmaceutical companies are still focusing most of their resources on a single SH group, prescribers. The lack of a systematic understanding of the infl uence of relationships between all SH groups has resulted in sales and marketing activities, which fail to address the issues pharmaceutical companies are faced with, such as low levels of public trust and decline in physician access. This paper presents a systematic approach, explaining what practical steps a pharmaceutical company can take to gather, map and act upon infl uence relationship information. Weniger anzeigen

This paper proposes a pragmatic model systematically assess the value of non-prescribers in order to optimise the allocation of scarcer promotional resources